Who are Naïve patients - MNDL therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, oseltamivir and chinese medicinal herbs, Pf-08032562.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/na-ve-patients-mndl-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Naïve patients - MNDL therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Naïve patients - MNDL therapy (Naïve patients - MNDL therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatoprotective agent. Area: Gastroenterology.

marketed Hepatoprotective agent Unknown Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Naïve patients - MNDL therapy (Naïve patients - MNDL therapy) — National Liver Institute, Egypt. MNDL therapy involves the use of a specific compound to target and modulate the activity of a particular enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naïve patients - MNDL therapy TARGET	Naïve patients - MNDL therapy	National Liver Institute, Egypt	marketed	Hepatoprotective agent	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
oseltamivir and chinese medicinal herbs	oseltamivir and chinese medicinal herbs	Capital Medical University	marketed	Neuraminidase inhibitor combined with herbal supplement	Influenza viral neuraminidase; herbal targets unknown
Pf-08032562	pf-08032562	Pfizer Inc.	marketed	unknown	unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Hepatoprotective agent class)

National Liver Institute, Egypt · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naïve patients - MNDL therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/na-ve-patients-mndl-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab